The interpretation of drug intoxication in death investigations is based on the available published literature. In the case of hydromorphone, the literature is limited. This report serves to facilitate the evaluation of cases where hydromorphone may be implicated in a fatality through the examination of 251 hydromorphone-positive cases in the province of Ontario from 1985 to 2003. Thirty-three of these cases were selected for review in greater detail. In four cases in which hydromorphone was the sole drug detected and death was attributed to hydromorphone toxicity, concentrations ranged from 77 to 2684 n~mL. Hydromorphone concentrations ranged from 21 to 441 ng/ml, in 28 cases in which at least one other drug was detected. In five deaths attributed to natural causes, blood hydromorphone concentrations ranged from 75 to 423 ng/mL. The results of this study emphasize the importance of case specific information. Fatalities due to hydromorphone occurred at 51 ng/ml and greater; however, tolerant users of this drug, as seen in the deaths attributed to natural causes, may achieve incidental concentrations that would otherwise he considered fatal. Hydromorphone was detected and quantitated using gas chromatography-mass spectrometry.
Introduction
Hydromorphone (Dilaudid | is a potent, semi-synthetic narcotic analgesic indicated for the relief of moderate to severe pain, and it is also prescribed in low doses as an antitussive for persistent, non-productive coughs (1) . Hydromorphone has also achieved popularity as a drug of abuse, and its addiction potential is similar when compared with morphine.
Hydromorphone hydrochloride is available in a variety of forms for oral administration, including controlled release (CR) and immediate release (IR) formulations, and parenteral and rectal administration. Recommended dosing is 1 to 4 mg every 4 to 6 h for pain; however, the amount of hydromorphone that an individual requires for satisfactory analgesia greatly varies depending on the severity and type of pain and any tolerance the individual has acquired through chronic opioid use (2) (3) (4) . Maximum mean plasma concentrations of 18 and 20 ng/mL were reported in a study where both IR and CR formulations, respectively, of hydromorphone were administered to 18 patients with chronic cancer pain (3) , and serum hydromorphone concentrations ranging from 2 to 49 ng/mL were reported in 43 patients with chronic severe pain of varying etiologies (4) .
Hydromorphone has been clinically determined to be approximately three to eight times as potent as morphine (5, 6) , and therefore, adverse reactions occur at lower concentrations compared with morphine. Toxicity to hydromorphone is dependent on tolerance, cross-tolerance, and upon the route of administration. The effects of hydromorphone in the event of an overdose include hypotension, respiratory depression, coma, and death.
In two deaths due to hydromorphone administered orally and parenterally, postmortem blood concentrations were 100 and 1200 ng/mL, respectively. The only other findings, considered noncontributory, in these cases were 0.010 g/100 mL of ethanol and a therapeutic concentration of diazepam, respectively (7) . From the same study, in two other deaths involving injected hydromorphone in mixed drug intoxications, postmortem blood concentrations of 20 and 500 ng/mL were reported. Ethanol and hydromorphone are both capable of producing mild to severe respiratory depression depending on concentration and tolerance of the individual. In combination, they have the potential to have additive detrimental effects on the central nervous system and, as such, this combination has proven to be lethal. Coingestion of ethanol and hydromorphone in fatal intoxications has been documented for blood ethanol concentrations of 0.160 and 0.090 g/100 mL with hydromorphone blood concentrations of 110 and 100 ng/mL, respectively (7, 8) .
The interpretation of postmortem hydromorphone concentrations in death investigations is limited to the aforementioned publications. Therefore, this study, through examination of 251 hydromorphone-positive fatalities in the province of Ontario from 1985 to 2003, adds to the existing literature and will provide assistance in the evaluation of these types of cases.
(1%) as a preservative and sodium citrate (0.5%) as an anticoagulant. The samples were stored at 4~ until analyzed.
Drug screening
Qualitative screening for opioids was performed using a Neogen | Hydromorphone Enzyme-Linked ImmunoSorbent Assay (ELISA) screening kit (Lexington, KY). A positive opioid ELISA screen test resulted in further analyses for the confirmation of the presence or absence of codeine, hydrocodone, morphine, or hydromorphone.
Blood and urine samples were analyzed for volatiles by dual column headspace gas chromatography (GC) with dual flameionization detectors (9) and screened by radioimmunoassay or ELISA for barbiturates, cocaine metabolite (benzoylecgonine), cannabinoid metabolites, acetaminophen, and salicylate. In addition, blood samples were subjected to a screening technique that is capable of detecting approximately 150 drugs and metabolites using GC with nitrogen-phosphorus detectors and GC-mass spectrometry (MS) (10) . Quantitation of drugs detected by screening procedures or those listed in the case history, including benzodiazepines, were confirmed and analyzed using a drug-specific method.
Quantitation of hydromorphone
This method was designed to simultaneously detect and measure free hydromorphone and morphine concentrations in biological samples.
Materials
All reagents used were analytical grade and solvents were high-performance liquid chromatography grade (BDH Canada Inc). High purity deionized water was obtained from a Millipore RiOsTM/Milli-Q | water purification system. Stock solution standards of hydromorphone, hydromorphone-d3, morphine, and morphine-d3 were obtained from Cerilliant (Round Rock, TX). Blank blood for sample dilutions, control samples, and the calibrations curves was obtained from Canadian Blood Services (Toronto, ON, Canada) or Pennsylvania Plasma (North Brunswick, N J) and was prescreened prior to use.
Sample extraction
The sample extraction method used for the analysis of hydromorphone and morphine prior to 2001 was a pHydrion Buffer| resin based extraction procedure using hydromorphone-d3 and morphine-d3 as internal standards. From 2001 to the present, the following method has been used.
Stock solutions of hydromorphone, morphine, and their deuterated analogues were prepared in methanol and stored at -15~ Internal standard solution (50 tK) containing 2.5 ~g/mL of hydromorphone-d3 and morphine-d3 was added to each 15-mL round-bottom centrifuge tube required for the assay. Calibration curves (31.3, 62.5, 125, 250, and 500 ng/mL) of hydromorphone and morphine were prepared based on a 1.0-mL aliquot of sample. An extraction blank and quality control sample were prepared using blank blood and analyzed with each assay. In circumstances where there was insufficient case blood available for analysis, volumes were brought up to 1.0 mL with blank blood and a dilution factor was taken into account.
Results obtained outside the working range of the method were re-extracted using a smaller aliquot of case blood and made up to volume with blank blood. After the addition of blood, each tube was vortex mixed and allowed to stand at room temperature for 10 min prior to extraction. To 1.0 mL of case sample, standards, and quality control samples, 3.0 mL of acetonitrile was added, then vortex mixed immediately (30 s) and centrifuged (3800 rpm) for 20 rain. The supernatant was decanted into a round-bottom disposable glass tube and evaporated to approximately 0.5 mL under nitrogen. Phosphate buffer (pH 6, 4.0 mL) was added to each tube and vortex mixed. All tubes were placed onto the Rapid Trace solid-phase extraction (SPE) robotics system (Zymark Corp., Hopkinton, MA) for automated extraction using an EZExtract TM Clean Screen | 200 rag/3 mL (CSDAU203) SPE column (Diagnostix, Mississauga, ON, Canada). The columns were conditioned with methanol, water, and 0.1M phosphate buffer (pH 6). The sample, once applied to the column, was rinsed with water and 0.1M acetate buffer (pH 4), allowed to dry for 4 rain, rinsed with methanol, and dried again for 5 rain. The cartridges were eluted with a solution of dichloromethane/isopropanol/ammonium hydroxide (78:20:2), and the eluant was collected in 16 x 100-mm disposable round-bottom glass tubes. The collection tubes were evaporated to dryness under nitrogen at 65~ using a Pierce Reacti-Therm IIF M heating module (Rockford, IL). The residue was dissolved in 1.0 mL of toluene, 5 tJL of acetic anhydride and 2 lJL of triethylamine were added, and then it was vortex mixed. The tubes were sealed with corks and allowed to stand for 60 min at room temperature. The organic layer was transferred to a 1.2-mL tapered microvial and evaporated to dryness under nitrogen at 65~ using a PierceReacti-Therm III TM heating module. Toluene (50 IlL) was added to the tapered microvial, crimp capped with a Teflon-lined septa, and vortex mixed.
GC-MS analysis
Sample extracts were analyzed using a Hewlett-Packard or Aglient GC-MS system equipped with an autosampler. A 2-1~L aliquot of the extract was injected into a split/splitless injector operated in the splitless mode at an inlet temperature of 270~ A DB-5MS column (30 m x 0.25-ram i.d., 0.25-1~m thickness, J&W Scientific, Folsom, CA) with a 1.5-to 2-m deactivated fused silica pre-column (0.25-ram i.d.) was used for analyte separation using ultra-high purity helium as a carrier gas. The GC oven temperature was programmed as follows: 100~ held for I rain, then ramped at 14~ to 290~ and held for 15 min. The transfer line temperature was 290~ Morphine and hydromorphone eluted at approximately at 15.2 and 15.7 min, respectively.
The MS was operated in the electron-impact ionization positive ion mode with a source temperature of 200~ Selected ion monitoring was used to scan two ions (m/z 285 and 327) for both morphine and hydromorphone and two ions (m/z 288 and 330) for both hydromorphone-d3 and morphine-d3 with dwell times of 100 ms for all ions monitored. The limit of detection for both hydromorphone and morphine was 7 ng/mL, and the limit of quantitation was 15 ng/mL. The calibration curves were linear to 1000 ng/mL. 
Case selection
The purpose of this study was to identify those cases that would provide the most probative information in hydromorphone-related fatalities, particularly at concentrations less than 100 ng/mL [the lowest reported concentration in a hydromorphone-attributed fatality (7)]. The case history and analytical findings for each case were reviewed. Exclusion of cases from the more in depth assessment included the presence of a toxic or fatal drug concentration other than hydromorphone, collection of a blood sample that was not from an intact blood vessel, cases where histories were incomplete, or if traces (between 7 and 15 ng/mL) of hydromorphone were detected. The number of cases that were excluded was 218.
The remaining 33 cases were placed into one of the three categories: 1. hydromorphone alone was detected, 2. only hydromorphone and ethanol were detected, and 3. where the finding of other drugs in addition to hydromorphone would, in isolation, be considered therapeutic or incidental findings. The manner and cause of death for each of these 33 cases were documented in the summary tables. The "manner of death" includes the following categories: accident, suicide, homicide, natural, and undetermined. The latter category was employed when a definitive decision was not reached for one of the other four possibilities. The "cause of death" was determined by the coroner with assistance from the pathologist and toxicologist. Cases (n = 4) where full toxicology drug screening was performed and hydromorphone was the sole drug detected ranged in concentration from 77 to 2684 ng/mL (Table I) . Table  II lists cases (n = 6) where hydromorphone and ethanol were the only drugs detected. The hydromorphone concentrations ranged from 65 to 163 ng/mL, whereas blood and urine ethanol concentrations ranged from 0.020 to 0.284 g/100 mL and 0.144 to 0.369 g/100 mL, respectively. Cases (n = 22) where drugs other than hydromorphone would, in isolation, be considered therapeutic or incidental findings are presented in Table III . In these cases, the hydromorphone concentrations ranged from 21 to 441 ng/mL.
|

Discussion
Hydromorphone is an effective drug for treatment of chronic severe pain, specifically in individuals with cancer (11); however, it is also a drug of abuse. This is evident not only from reports in the literature (12, 13) , but also from the increasing number and nature of hydromorphone-positive cases over the past 19 years in this laboratory in death investigation cases. A peak of 63 cases was reached in 2003 ( Figure 1 ). This increase in the number of hydromorphone-positive cases cannot be explained solely by the increase in the number of cases submitted to this laboratory, but may be due in part to the greater widespread use and abuse of hydromorphone and the implementation of an opioid immunoassay screening procedure in 2001.
In efforts to assist in toxicological death investigations, hydromorphone-positive cases between 1985 and 2003 were reviewed. Of particular interest, were cases where the cause of death was hydromorphone intoxication and the concentration was less than the previously reported fatal level of 100 ng/mL (7, 8) . We report three fatalities attributed to hydromorphone that occurred below this reported concentration.
Hydromorphone as the sole intoxicant in a case appears to be rare, and death investigations involving hydromorphone often reveal the presence of other drugs. In the present study, only four cases where full toxicology drug screening was undertaken had hydromorphone as the sole drug detected (cases 2-5). The lowest concentration detected in a case, where hydromorphone was the only drug present and the death was attributed solely to hydromorphone intoxication, was 77 ng/mL (case 2). Further evidence in support of fatal concentrations less than 100 ng/mL comes from two cases where the cause of death was attributed to hydromorphone intoxication and the other drug findings were considered to be incidental. In the first case, a concentration of 51 ng/mL (case 17) from injected hydromorphone was detected along with a therapeutic concentration of citalopram, and a concentration of 70 ng/mL of hydromorphone with traces of morphine, diazepam, and nordiazepam were detected in the second case (case 23). The detection of traces of morphine (< 15 ng/mL), diazepam (< 0.1 mg/L), and nordiazepam (< 0.1 mg/L) would not be expected to exert any significant central nervous system (CNS) depressive effects.
The combination of ethanol and hydromorphone tends to exacerbate respiratory depressant effects and as such, the fatal concentration of hydromorphone may be lower in the presence of a blood-alcohol concentration (BAC) substantial enough to cause the CNS depression. Like hydromorphone, toxicity to ethanol is dependent on the individual's tolerance to alcohol. To Upset over recent death of daughter; Acute congestion in lungs hydromorphone intoxication UAC: 0.272 and diffuse edema * Blood concentrations of hydromorphone (ng/mL) and blood ([3AC) and urine (UAC) ethanol (gl100 mL) are reported, and the site of blood collection is listed if known H = heart blood; P = peripheral blood. date, previously published hydromorphone and ethanol intoxications have documented this fatal combination at 110 and 100 ng/mL with BACs of 0.160 and 0.090 g/100 mL, respectively (7, 8) . Whereas in this study, four fatalities (cases 6, 7, 16, and 19) with hydromorphone concentrations ranging from 50 to 72 ng/mL occurred below the previously published levels. In case 8, where the BAC was considered noncontributory, a hydromorphone concentration of 102 ng/mL was detected. These five cases, examined more closely because of the hydromorphone levels (essentially at or below 100 ng/mL), demonstrated an inverse relation between hydromorphone concentration and BAC required to cause fatalities, as depicted in Figure 2 . Development of tolerance to opioids results in decreased CNS depressant effects and the potential for increased dosing requirements to achieve the same effects. Therefore, individuals can achieve concentrations of the active drug within their system well in excess of a concentration that may be considered toxic or fatal in a nontolerant individual. In five cases, where hydromorphone was prescribed for pain management in cancerrelated deaths, concentrations ranged from 75 to 423 ng/mL (cases 1, 26, 29, 31, and 32). These concentrations are much greater than therapeutic levels of hydromorphone found in clinical studies (3, 4) ; however, they were considered to be incidental findings in these cases. This hydromorphone concentration range (75 to 423 ng/mL) overlaps with concentrations in our study where hydromorphone alone was determined to have caused death (51 to 2684 ng/mL) and with concentrations observed in cases where hydromorphone in combination with other drugs including alcohol (21 to 441 ng/mL) were related to the fatality. This finding emphasizes the role of tolerance in the interpretation of drug levels where the individuals were being treated for chronic cancer pain.
The concentrations in cases of hydromorphone intoxication at least partly attributed to intravenous (i.v.) injection, as there was evidence either on the body, at the scene, or provided by witnesses indicating i.v. administration, ranged from 21 to 153 ng/mL. In these 11 cases, the cause of death was attributed to hydromorphone alone (cases 3, 17, 23, and 30), hydromorphone and ethanol intoxication (cases 6, 7, and 19), mixed drug intoxication (cases [12] [13] [14] , and hydromorphone and ischemic heart disease (case 21).
A change in extraction methodology in 2001 from an XAD resin-based extraction to a SPg-based extraction was necessitated by an increased requirement for quantitation of hydromorphone and morphine. The SPE method is faster, automated, less labor intensive, requires fewer materials and solvents, and a larger number of cases can be extracted at one time compared to the XAD method.
Each death investigation case must be evaluated on an individual basis and must take into account medical history, tolerance to hydromorphone, cross-tolerance with other opioids, and the presence of and tolerance to other CNS depressant drugs. This compilation of data will assist professionals involved in death investigations with the interpretation of fatal concentrations of hydromorphone alone, or with other drugs, as well as the interpretation of hydromorphone concentrations in individuals on chronic drug treatment for pain control. 
